Can This Tiny Biotech Take Down Amgen?
The biotech version of David vs. Goliath just got more interesting, with the $3.7-billion-market-cap Mirati Therapeutics (NASDAQ: MRTX) posting data this week for its KRAS inhibitor MRTX849 suggesting it can be competitive with AMG 510 from Amgen (NASDAQ: AMGN), which weighs in at a market cap of $126 million.
You can't make firm predictions on drugs from two different uncontrolled clinical trials, especially with low numbers of patients, but qualitatively, MRTX849 looks like it can stack up against AMG 510.
Here's how Mirati's data presented this week at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics stacks up against Amgen's data from the European Society for Medical Oncology late last month.
Source Fool.com
